Shipo Wu

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Shipo Wu, Jianying Huang, Zhe Zhang et al. · The Lancet Infectious Diseases · 2021 · 300 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15

A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

Shipo Wu, Gongxun Zhong, Jun Zhang et al. · Nature Communications · 2020 · 286 citations · Full text

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17

Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial

Fengcai Zhu, Alie Wurie, Lihua Hou et al. · The Lancet · 2016 · 200 citations

Veterinary Medicine, Immunology, Infectious Diseases +12

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

Fengcai Zhu, Lihua Hou, Jingxin Li et al. · The Lancet · 2015 · 187 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

Jingxin Li, Shipo Wu, Xiling Guo et al. · The Lancet Respiratory Medicine · 2022 · 170 citations · Full text

Life Sciences, Immunology, Infectious Diseases +15